Login
$XBIO
$1.49 -$0.17 (10.24%) Close

$XBIO 8-K SEC Filings

Filed On Filing
13 Nov 2026 8-K: Results of Operations and Financial Condition

Proposed share exchange transaction expected to create a multi-indication clinical stage company focused on targeting neutrophil extracellular traps (NETs)

23 Sep 2026 8-K: Regulation FD Disclosure

Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026

16 Sep 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

______________________________________________________________________________

07 Aug 2026 8-K: Results of Operations and Financial Condition

Expanded collaborative research initiatives reinforce the Company's long-term

13 May 2026 8-K: Results of Operations and Financial Condition

Advancements across investigator-initiated studies, translational research and

24 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

Xenetic Biosciences, Inc. (the “Company”) hereby grants the following shares of restricted stock (“Restricted Stock”) pursuant to its Amended and Restated Equity Incentive Plan (as may be amended, the “Plan”). The terms of the grant are ...

13 Mar 2026 8-K: Results of Operations and Financial Condition

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers

09 Jan 2026 8-K: Other Events

On December 11, 2025, Xenetic Biosciences, Inc. (the “Company”) announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), originally scheduled for December 11, 2025, had been adjourned until January 8, 2026 in order ...

11 Dec 2025 8-K: Regulation FD Disclosure

FRAMINGHAM, MA – (December 11, 2025) – Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers,...

13 Nov 2025 8-K: Results of Operations and Financial Condition

Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners

14 Oct 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Xenetic Biosciences, Inc., a Nevada corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, 735,000 shar...

13 Aug 2025 8-K: Results of Operations and Financial Condition

Expanded strategic partnership with The Scripps Research Institute to advance

14 May 2025 8-K: Results of Operations and Financial Condition

Strategic focus on exploratory investigator-initiated clinical studies with institutional partners

10 Apr 2025 8-K: Changes in Registrant's Certifying Accountant

We have read the statements made by Xenetic Biosciences, Inc. under Item 4.01 of its Form 8-K. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Xene...

19 Mar 2025 8-K: Results of Operations and Financial Condition

Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers

13 Dec 2024 8-K: Submission of Matters to a Vote of Security Holders

On December 11, 2024, Xenetic Biosciences, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted on the following four proposals and cast th...

13 Nov 2024 8-K: Results of Operations and Financial Condition

– Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications

07 Nov 2024 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Company is advancing DNase-based oncology program towards clinical

31 Oct 2024 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

14 Aug 2024 8-K: Results of Operations and Financial Condition

Ongoing preclinical studies with data expected before year end

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support